Drilldown: Medicines
Appearance
Medicines > classes
:
Phenethylamine
or
Research material
or
[[:Category:Overactive_bladder_medications|Overactive bladder medication]] 
:
Phenethylamine
or
Research material
or
[[:Category:Overactive_bladder_medications|Overactive bladder medication]] 
Use the filters below to narrow your results.
generic:
mechanism:
5-HT2A agonist (26) ·
Monoamine releasing agent (9) ·
GABAA positive allosteric modulator (8) ·
CB1/CB2 agonist (7) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Potent 5-HT2A agonist (5) ·
LSD analogue; 5-HT2A agonist (4) ·
Prodrug of LSD; 5-HT2A agonist (4) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
None (2) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
NMDA antagonist (2) ·
Prodrug of GHB (2)
None (132) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-000006DE-QINU`"', '"`UNIQ--vote-000006DF-QINU`"', '"`UNIQ--vote-000006E0-QINU`"' (1) ·
'"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1) ·
'"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"' (1)
None (132) ·
25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed (1) ·
5 mg PO once daily; titrate to 10 mg after 2 weeks if needed (1) ·
IR 5 mg PO BID-TID; ER 5-10 mg PO daily, titrate; transdermal patch 3.9 mg/d twice weekly (OTC) (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
None (132) ·
25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1) ·
5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel (1) ·
5, 10 mg tablets (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
None (131) ·
2-3 hours (parent and active N-desethyl metabolite)'"`UNIQ--ref-000006E1-QINU`"' (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
Not well characterized (1) ·
~45-68 hours'"`UNIQ--ref-00000DFE-QINU`"' (1) ·
~50 hours'"`UNIQ--ref-00000C4E-QINU`"' (1)
None (131) ·
25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) ·
Not formally characterized in humans. (1) ·
Not well characterized (1) ·
~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' (1) ·
~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' (1)
None (131) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3) ·
Not established (1)
Showing below up to 161 results in range #1 to #161.
1
2
- 2-AI
- 2-FA
- 2-FDCK
- 2-FMA
- 25B-NBOH
- 25B-NBOH
- 25B-NBOMe
- 25B-NBOMe
- 25C-NBOH
- 25C-NBOH
- 25C-NBOMe
- 25C-NBOMe
- 25I-NBOH
- 25I-NBOH
- 25I-NBOMe
- 25I-NBOMe
- 25N-NBOMe
- 25N-NBOMe
- 2C-B
- 2C-B-FLY
- 2C-B-FLY
- 2C-C
- 2C-C
- 2C-D
- 2C-D
- 2C-E
- 2C-E
- 2C-I
- 2C-I
- 2C-P
- 2C-P
- 2C-T-2
- 2C-T-2
- 2C-T-7
- 2C-T-7
3
4
5
A
B
C
D
E
F
G
H
I
J
L
M
- MCPP
- MDPV
- Mephedrone
- MET
- Methallylescaline
- Methallylescaline
- Methcathinone
- Methoxetamine
- Methylnaphthidate
- Methylone
- Metizolam
- Mexedrone
- MiPLA
- MiPT
- Mirabegron

